Canadian National Antimicrobial Prescribing Survey
Antimicrobial resistance (AMR) is a global health crisis. The progressive loss of antimicrobial effectiveness is reducing our ability to treat and prevent infectious diseases, with profound impacts on our healthcare system, global trade, agriculture, environment and economy.
Two pillars of the Pan-Canadian Framework on Antimicrobial Resistance and the Pan-Canadian Action Plan on AMR are surveillance and antimicrobial stewardship. These frameworks have identified a need to implement a robust system for collecting antimicrobial utilization data to support antimicrobial stewardship efforts.
The NAPS™ was first piloted in Canada in 2018/2019 based on a customized version of the Australian Hospital NAPS™ tool with Sinai Health Research Ethics Board approval, and is now being used in over 100 hospitals in all provinces for quality improvement and research purposes. Canadian NAPS is in its fifth year of implementation, and has been instrumental in providing a national estimate of antimicrobial use and appropriateness in hospitals across Canada.
Dashboard Reports & Benchmarking
Reporting capabilities include appropriateness by indication, appropriateness by prescribed antimicrobial, compliance by guidelines, and appropriateness comparisons between sites and all other benchmarking sites nationally. With permission from participating facilities, data is contributed to national reporting to facilitate the Pan-Canadian AMR action plans.
Registered hospital sites across Canada by Region
Characteristics of Registered Hospital Sites
Large (>400 beds)
Medium (200-399 beds)
Small (<200 beds)
Based on acute bed number reported at time of registration.
Population Centre of Location
Large Urban (>100K)
Medium Urban (30K-99,999K)
Small Urban (1K-29,999K)
Rural (<1000 population)
NAPS™ is supported by the National Centre for Antimicrobial Stewardship and the Australian Commission on Safety and Quality in Health Care.
All data is protected and utilized under the ethics and requirements of the National Health and Medical Research Council, Australia and Melbourne Health, Australia (QA2013066), and Sinai Health System, Canada (QI).